The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of organ function based standard exclusion criteria in diffuse large b-cell lymphoma (DLBCL) patients: Who gets left behind?
 
Arushi Khurana
No Relationships to Disclose
 
Raphael Mwangi
No Relationships to Disclose
 
Grzegorz S. Nowakowski
Consulting or Advisory Role - Celgene (Inst); Genentech (Inst); MorphoSys (Inst)
Research Funding - Celgene (Inst); MorphoSys (Inst); NanoString Technologies (Inst)
 
Thomas Matthew Habermann
Consulting or Advisory Role - Celgene; Kite/Gilead
 
Stephen M. Ansell
Honoraria - Research to Practice; WebMD
Research Funding - Affimed Therapeutics (Inst); AI Therapeutics (Inst); Bristol-Myers Squibb (Inst); Pfizer (Inst); Regeneron (Inst); Seagen (Inst); Trillium Therapeutics (Inst)
 
Betsy LaPlant
No Relationships to Disclose
 
Brian K. Link
Consulting or Advisory Role - Abbvie; Genentech/Roche; Karyopharm Therapeutics
Research Funding - Pharmacyclics/Janssen (Inst)
Travel, Accommodations, Expenses - Genentech/Roche
 
James Robert Cerhan
Consulting or Advisory Role - Janssen; Janssen
Research Funding - Celgene; NanoString Technologies
 
Matthew J. Maurer
Consulting or Advisory Role - Kite, a Gilead company; MorphoSys; Pfizer
Research Funding - Celgene (Inst); NanoString Technologies (Inst)
 
Thomas E. Witzig
Consulting or Advisory Role - Abbvie/Genentech (Inst); Celgene (Inst); Cellectar; Epizyme; Immune Design; Incyte (Inst); Karyopharm Therapeutics; MorphoSys (Inst); Portola Pharmaceuticals; Seagen (Inst); Tessa Therapeutics
Research Funding - Acerta Pharma (Inst); Celgene (Inst); Kura Oncology (Inst)